同等降脂幅度不同强度他汀类药物对急性冠脉综合征预后的影响

Effect of Different Intensity Statins at the Same Lipid-lowering Range on Prognosis of Acute Coronary Syndrome

目的:探讨不同强度的3类他汀治疗对急性冠脉综合征(ACS)的疗效。方法:选取2014年1月至2014年6月茂名石化医院收治的180例ACS患者,治疗应用瑞舒伐他汀5 mg/d、瑞舒伐他汀10 mg/d、阿托伐他汀10 mg/d、阿托伐他汀20 mg/d、辛伐他汀20 mg/d或辛伐他汀40 mg/d。结果:6组治疗前血脂水平比较,差异无统计学意义(P>0.05)。3类中等强度他汀治疗均可明显降低LDL-C水平比较,差异具有统计学意义(P<0.05),6组患者不良反应和心血管事件比较,差异无统计学意义(P>0.05)。结论:中等强度的瑞舒伐他汀、阿托伐他汀、辛伐他汀均是治疗ACS的安全有效的治疗手段。

Objective To compare effectiveness of 3 statins of moderate-intensity used to treat acute coronary syndrome （ACS）. Methods A total of 180 patients with ACS were assigned to receive either 5mg/day rosuvastatin, 10mg/day rosuvastatin, 10mg/ day atorvastatin, 20mg/day atorvastatin, 20mg/day simvastatin or 40mg/day. Results No difference of blood lipid levels between pre and post treatment was discovered among 6 treatment groups （P〉0.05）. Three statins of moderate-intensity all could significantly reduced LDL-C levels （P〈0.05） with no difference in adverse events （P〉0.05） and cardiovascular events （P〉0.05）. Conclusion Moderate-intensity rosuvastatin, rosuvastatin and atorvastatin are all safe and effective approaches for ACS.